

Not for release, or for publication or distribution, directly or indirectly in or into the United States, Australia, Hong Kong, Canada, Japan, New Zealand or South Africa.

PRESS RELEASE  
Lund, Sweden, 13 March 2012



## **Prospectus regarding BioInvent's rights issue made public**

The prospectus regarding BioInvent's rights issue has now been made public and is available on BioInvent's website, [www.bioinvent.com](http://www.bioinvent.com), as well as on Avanza Bank's website, [www.avanza.se](http://www.avanza.se) under "För företag/Corporate finance/Pågående uppdrag". The prospectus will be distributed by mail to BioInvent's directly registered shareholders.

--END--

### **To the editors:**

#### **About BioInvent**

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics.

The company's competitive position is underpinned by n-CoDeR<sup>®</sup>, a proprietary antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at [www.bioinvent.com](http://www.bioinvent.com).

### **For further information, please contact:**

#### ***BioInvent International AB***

Svein Mathisen  
President & CEO  
Phone: +46 (0)46 286 85 67  
Mobile: +46 (0)708 97 82 13  
E-mail: [svein.mathisen@bioinvent.com](mailto:svein.mathisen@bioinvent.com)

Sten Westerberg  
Vice President, Investor Relations  
Phone: +46 (0)46 286 85 52  
Mobile: +46 (0)768 68 50 09  
E-mail: [sten.westerberg@bioinvent.com](mailto:sten.westerberg@bioinvent.com)

#### **BioInvent International AB (publ)**

Co. reg. No. 556537-7263,  
Visiting address: Sölvegatan 41  
Mailing address: SE-223 70 LUND  
Phone: +46 (0)46 286 85 50  
[info@bioinvent.com](mailto:info@bioinvent.com)  
[www.bioinvent.com](http://www.bioinvent.com)

## About BioInvent

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics.

The company's competitive position is underpinned by an in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe, Servier, UCB and XOMA. More information is available at [www.bioinvent.com](http://www.bioinvent.com).

*The information was submitted for publication at 3.30 p.m. CET, on 13 March, 2012.*

## IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in BioInvent International AB. Any invitation to the persons concerned to subscribe for shares in BioInvent is made only through the prospectus that BioInvent made public on 13 March 2012.

This press release may not be published or distributed, directly or indirectly in or into the United States, Australia, Hong Kong, Canada, Japan, New Zealand, South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions or would require such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No subscription rights, BTAs (interim shares) or new shares will be registered under the United States Securities Act of 1933 ("**Securities Act**") or securities legislation in any other state or other jurisdiction in the United States and may not be offered, subscribed, sold or transferred, directly or indirectly within the United States, other than pursuant to an exemption from the registration requirements of the Securities Act and in accordance with securities laws in relevant state or other jurisdiction in the United States.

This press release may contain forward-looking statements which reflect BioInvent's current view on future events and financial and operational development. Words such as "intend", "expect", "anticipate", "may", "believe", "plan", "estimate" and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties because they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the real outcome could differ materially from the forward-looking statements.